Related Experiment Video
Updated: May 10, 2026
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Emerging therapies for rheumatoid arthritis
Peggy Jacques1, Filip Van den Bosch
1Ghent University Hospital, Department of Rheumatology, De Pintelaan 185, Gent, Belgium.
Expert Opinion on Emerging Drugs
|June 4, 2013
Summary
New rheumatoid arthritis (RA) treatments are needed as many patients do not respond to biologics. Small molecules targeting JAK, Syk, and PDE4 show promise for future RA therapies.
Area of Science:
- Rheumatology and immunology
- Drug discovery and development
Background:
- Biologic therapies have advanced rheumatoid arthritis (RA) treatment.
- A significant portion of RA patients (up to 40%) exhibit non-responsiveness to current biologic therapies.
Purpose of the Study:
- To review emerging treatment strategies for rheumatoid arthritis.
- To explore novel therapeutic targets beyond TNF inhibitors.
Main Methods:
- Overview of ongoing clinical trials for RA.
- Discussion of molecules targeting cytokines other than TNF.
- Exploration of chemokine-directed drugs and small molecular inhibitors.
Main Results:
- Several new treatment avenues are under investigation.
- Targeting cytokines beyond TNF and chemokines represents a developing area.
- Small molecular inhibitors are a key focus for future RA therapies.
Conclusions:
- Rheumatoid arthritis necessitates continuous development of new treatments due to its chronic and potentially disabling nature.
- Small molecules inhibiting Janus kinase (JAK), spleen tyrosine kinase (Syk), and phosphodiesterase 4 (PDE4) offer promising therapeutic avenues for RA management.
Related Concept Videos
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:20Rheumatic Heart Disease IV: Nursing Management
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...